CV6 Therapeutics is a pioneering biotech company headquartered in Belfast, Northern Ireland, dedicated to disrupting the cornerstone therapy markets in oncology and inflammatory diseases.

Our approach has led to developing first-in-class, best-in-class medications to address global unmet medical needs.

Our innovative pipeline promises to improve efficacy and patient outcomes. It includes our first oncology drug, CV6-168, currently in Phase 1a trials, and our inflammatory diseases asset, CV6-1271.

We’re committed to transforming patient care with cutting-edge science.